Engineered immune cells take aim at Hard-to-Treat leukemia

NCT ID NCT06071624

Recruiting now Disease control Sponsor: Huda Salman Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called CD4CAR T cells for people with chronic myelomonocytic leukemia (CMML) that has come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. The main goals are to find a safe dose and see if it can reduce cancer in the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD4CAR T cells (immune cells engineered to target CD4-positive cells)
What this could lead to: If successful, this could point toward a new treatment option for people with CMML that has not responded to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so safety and dosing are still being figured out. It may not work or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelomonocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOMONOCYTIC LEUKEMIA

Contacts and locations

Locations

Albert Einstein Health Network
NOT_YET_RECRUITING

The Bronx, New York, 10467, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida 33136
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.